Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Respiratory Distress Syndrome, Hyperoxia, Prematurity
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 3 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: ASTX660, Midazolam, Itraconazole; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Cardiovascular Disease, Arterial Stiffness, Germline Mutation in the NOTCH 3 Gene, Pathogenesis of CADASIL, Clinical Phenotype of CADASIL
Interventions: MRI; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2041
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions: RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Menopause
Interventions: Premarin® (oral) vs. Alora® (transdermal); Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 42 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Visual Acuity
Interventions: Acuvue Oasys 1 Day for Astigmatism, TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 7 more

Conditions: Healthy Participants
Interventions: AZD0780, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Pain
Interventions: Complementary and Integrative Therapies, Standard Rehabilitative Care; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Participants
Interventions: EE/LNG, Baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Bipolar I Disorder
Interventions: Quetiapine Fumarate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Chronic Pain Syndrome
Interventions: DockTales, REDCap monitoring; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Darigabat, Carbamazepine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
Interventions: Follow-Up, Medical Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2044
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Pain
Interventions: Spinal cord stimulator; Device
Lead sponsor: The Center for Clinical Research, Winston-Salem, NC; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stroke, Cerebrovascular Accident, Hemiparesis
Interventions: Paired corticospinal-motoneuronal stimulation (PCMS), Sham stimulation; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Failure, Systolic Bundle Branch Block, Left
Interventions: LBBAP Therapy, LOT-CRT, ICD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Allergic Reaction
Interventions: DESF, Epinephrine Injection; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Visual Acuity
Interventions: ACUVUE® OASYS 1-DAY; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Maitland, Florida • Tallahassee, Florida + 4 more

Conditions: Brain MRI
Interventions: Brain MRI, Brain MRI - SOC and spiral, Brain MRI - spiral; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Age-Related Macular Degeneration
Interventions: KH631; Drug
Lead sponsor: Chengdu Origen Biotechnology Co., Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more

Conditions: Joint Engagement + Enhanced Milieu Training, Joint Engagement + Enhanced Milieu Training+Augmentative Communication (AAC)
Interventions: JAE Intervention; Behavioral
Lead sponsor: Autism Speaks; Other
Eligibility: 5 Years to 8 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee

Conditions: Bioequivalence
Interventions: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Natural History Study of CADASIL

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions

DockTales for Chronic Pain

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Comparison of 1000 Hertz (Hz), Burst, and Standard Spinal Cord Stimulation in Chronic Pain Relief

Spinal Plasticity to Enhance Motor Retraining After Stroke

Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing

Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome

Clinical Evaluation of Senofilcon A Contact Lenses Using a Novel Manufacturing Technology

The Spiral MRI Study

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Developmental and Augmented Intervention for Facilitating Expressive Language

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants